Geneuro SAPAR Geneuro Stock Report

GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 17 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.